Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...
Wall Street is loving this. Analysts at JPMorgan and RBC Capital see this as a major boost for Intra-Cellular's long-term game plan. CAPLYTA's extended revenue runway has turned heads, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results